Connecticut Children's Hospital

Hartford, Connecticut 06106

7 studies enrolling now · 22 studies all time

What they study most

Asthma, Atypical Teratoid/Rhabdoid Tumor, Brain Tumors, Choroid Plexus Neoplasms, Clear Cell Sarcoma, Craniopharyngioma, DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma, Dysembryoplastic Neuroepithelial Tumor, Embryonal Tumor With Multilayered Rosettes, Ependymoma, Ewing Sarcoma

Studies at this site

• Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors — Recruiting now
• Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas — Recruiting now
• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma — Recruiting now
• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy — Recruiting now
• Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma — Recruiting now
• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma — Recruiting now
• Beat Childhood Cancer Specimen Banking and Data Registry — Recruiting now
• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma — Running, not enrolling
• Neuroblastoma Maintenance Therapy Trial — Running, not enrolling
• Preventing Asthma in High Risk Kids — Running, not enrolling
• Molecular-Guided Therapy for Childhood Cancer — Completed
• Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma — Completed
• Trial of Tolcapone With Oxaliplatin for Neuroblastoma — Stopped early
• Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide — Completed
• Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma — Completed
• Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission — Completed
• Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma — Completed
• Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer — Completed
• Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma — Stopped early
• Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma — Stopped early
• Safety and Efficacy Study in Infant With SBS — Stopped early
• Pediatric Alliance for International Neurogastrointestinal Functional Research — Completed